Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, ...

Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...